In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae | Zendy

Naoyuki Miyashita | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae

Author(s) -

Naoyuki Miyashita

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/48.3.403

Subject(s) - telithromycin , ketolide , roxithromycin , erythromycin , azithromycin , clarithromycin , chlamydia , antibacterial agent , microbiology and biotechnology , chlamydophila pneumoniae , streptococcus pneumoniae , antibiotics , mycoplasma pneumoniae , respiratory tract infections , medicine , biology , chlamydiaceae , immunology , pneumonia , respiratory system

The in vitro activity of telithromycin, a new ketolide, was compared with those of roxithromycin, azithromycin, clarithromycin and erythromycin A against 20 strains of Chlamydia pneumoniae. The MICs and minimal chlamydiacidal concentrations of telithromycin for the 20 C. pneumoniae strains both ranged between 0.031 and 0.25 mg/L. Telithromycin was twice as active as roxithromycin, azithromycin and erythromycin A, but less active than clarithromycin. These results appear to indicate that telithromycin is an effective antibiotic that should play some role in the treatment of respiratory tract infections caused by C. pneumoniae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research